LipidViro Tech, Inc., a development stage biotechnology company, engages in the research and commercial development of two primary platforms: d-OSAB Therapy, a treatment targeting cardiovascular disease and stroke; and PathPure, a purification process for production of pathogen-free biologics. LipidViro d-OSAB Therapy is a new, re-engineered doseable form of a traditional therapy known as OSAB-uc for uncontrolled dosing. Proprietary technology developed and owned by LipidViro Tech produces the doseable OSAB therapy, known as d-OSAB. Products or Services The company is conducting pre-clinical laboratory research focused on the development of therapeutics and biological products that utilize its proprietary d-OSAB platform, processes and equipment. LipidViro Tech, Inc. was founded in 2003.